Platelet microparticle formation and thrombin generation under high shear are effectively suppressed by a monoclonal...

Area of Science:

• Hematology
• Biochemistry
• Cardiovascular Research

Background:

• Platelet microparticles (MPs) and thrombin generation contribute to thrombosis under high shear stress.
• Understanding the mechanisms of MP formation and thrombin generation is crucial for developing anti-thrombotic therapies.

Purpose of the Study:

• To investigate the efficacy of inhibiting the GPIbα-von Willebrand factor (vWF) interaction versus GPIIb/IIIa inhibition in reducing MP formation and thrombin generation under high shear forces.
• To compare the effectiveness of monoclonal antibody Ib-23 (Mab Ib-23) targeting GPIbα with GPIIb/IIIa antagonists.

Main Methods:

• Platelet-rich plasma (PRP) was subjected to high shear (5,000 s⁻¹) in the presence of GPIbα antagonist (Mab Ib-23) or GPIIb/IIIa antagonists (abciximab, tirofiban, eptifibatide).
• MP formation and aminophospholipid exposure were quantified using flow cytometry (CD41-PE and annexin-V-FITC).
• Thrombin generation was measured in PRP, and the contribution of MPs to thrombin generation was assessed.

Main Results:

• Approximately 40% of thrombin generation was mediated by the MP fraction.
• Blockade of GPIbα with Mab Ib-23 reduced MP formation and thrombin generation by 50%, outperforming GPIIb/IIIa inhibitors.
• Combining Mab Ib-23 with a GPIIb/IIIa inhibitor further reduced MP formation to ~30% and partially inhibited thrombin-induced platelet aggregation.

Conclusions:

• Inhibition of the GPIbα-vWF interaction is a highly effective strategy for reducing prothrombotic MP generation and thrombin formation under high shear rates.
• Mab Ib-23 demonstrates superior efficacy compared to GPIIb/IIIa antagonists in this context.
• Targeting GPIbα offers a promising therapeutic approach for conditions involving arterial stenosis and high shear stress.